[SCHEDULE 13G] CYBIN INC. Passive Investment Disclosure (>5%)

Rhea-AI Filing Summary

OrbiMed Advisors LLC and OrbiMed Capital LLC report significant ownership stakes in Cybin Inc.’s common stock. OrbiMed Advisors reports beneficial ownership of 1,417,900 shares, or 2.8% of the class, while OrbiMed Capital reports 2,422,600 shares, or 4.9% of the class.

Together, the reporting persons hold 7.7% of Cybin’s common shares in the aggregate on behalf of other persons entitled to dividends or sale proceeds. The positions are certified as being held in the ordinary course of business and not for the purpose of changing or influencing control of Cybin.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cybin Inc.

(Name of Issuer)

Common Stock, no par value

(Title of Class of Securities)

23256X100

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23256X100

1

Names of Reporting Persons

ORBIMED ADVISORS LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,417,900.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,417,900.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,417,900.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.8 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 23256X100

1

Names of Reporting Persons

ORBIMED CAPITAL LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,422,600.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,422,600.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,422,600.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.9 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cybin Inc.
(b)	Address of issuer's principal executive offices: 100 King Street West, Suite 5600, Toronto, Ontario, Canada M5X 1C9
Item 2.
(a)	Name of person filing: OrbiMed Advisors LLC OrbiMed Capital LLC
(b)	Address or principal business office or, if none, residence: 601 Lexington Avenue, 54th Floor New York, NY 10022
(c)	Citizenship: Please refer to Item 4 on each cover sheet for each filing person.
(d)	Title of class of securities: Common Stock, no par value
(e)	CUSIP No.: 23256X100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: OrbiMed Advisors LLC: 1,417,900 OrbiMed Capital LLC: 2,422,600
(b)	Percent of class: OrbiMed Advisors LLC: 2.8% OrbiMed Capital LLC: 4.9%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 2,422,600
	(ii) Shared power to vote or to direct the vote: OrbiMed Advisors LLC: 1,417,900 OrbiMed Capital LLC: 0
	(iii) Sole power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 0 OrbiMed Capital LLC: 2,422,600
	(iv) Shared power to dispose or to direct the disposition of: OrbiMed Advisors LLC: 1,417,900 OrbiMed Capital LLC: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Reporting Persons hold 7.7% of the shares of Common Stock in the aggregate on behalf of other persons who have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, such securities. OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power over the shares of Common Stock through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares of Common Stock reported herein.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ORBIMED ADVISORS LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	02/17/2026

ORBIMED CAPITAL LLC

Signature:	/s/ Carl L. Gordon
Name/Title:	Carl L. Gordon/Member
Date:	02/17/2026

FAQ

What ownership stakes in Cybin Inc. does OrbiMed report in this Schedule 13G?

OrbiMed Advisors LLC reports beneficial ownership of 1,417,900 Cybin common shares, or 2.8% of the class. OrbiMed Capital LLC reports 2,422,600 shares, representing 4.9%. These holdings reflect their combined investment interest in Cybin’s common stock.

What is the total Cybin (CYBN) stake held on behalf of others by OrbiMed?

The reporting persons state they hold 7.7% of Cybin’s common stock in the aggregate on behalf of other persons. Those other persons have rights to receive dividends or proceeds from share sales, while OrbiMed entities exercise investment and voting power over the shares.

Who are the reporting persons in the Cybin Inc. Schedule 13G filing?

The filing identifies OrbiMed Advisors LLC and OrbiMed Capital LLC as the reporting persons for Cybin Inc. Both are organized in Delaware, with a principal business office at 601 Lexington Avenue, 54th Floor, New York, NY 10022, managing investment and voting power over the shares.

Does OrbiMed seek to influence control of Cybin Inc. with this ownership?

The filing certifies the securities were acquired and are held in the ordinary course of business. It explicitly states they were not acquired and are not held to change or influence control of Cybin, except for activities solely tied to a nomination under Rule 240.14a-11.

Who exercises voting and investment power over Cybin shares held by OrbiMed?

OrbiMed Advisors LLC and OrbiMed Capital LLC exercise investment and voting power through a management committee of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. Each individual disclaims beneficial ownership of the Cybin common shares reported in this Schedule 13G filing.

What class of Cybin securities is covered by this Schedule 13G?

The filing covers Cybin Inc. common stock with no par value. It references the class by its CUSIP number 23256X100. All reported ownership percentages and share amounts relate specifically to this common stock class, not to any preferred or other security types.